Eintrag weiter verarbeiten
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements
Gespeichert in:
| Zeitschriftentitel: | Genes, Chromosomes and Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Genes, Chromosomes and Cancer, 59, 2020, 1, S. 50-57 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Javanmardi, Niloufar Fransson, Susanne Djos, Anna Umapathy, Ganesh Östensson, Malin Milosevic, Jelena Borenäs, Marcus Hallberg, Bengt Kogner, Per Martinsson, Tommy Palmer, Ruth H. Javanmardi, Niloufar Fransson, Susanne Djos, Anna Umapathy, Ganesh Östensson, Malin Milosevic, Jelena Borenäs, Marcus Hallberg, Bengt Kogner, Per Martinsson, Tommy Palmer, Ruth H. |
|---|---|
| author |
Javanmardi, Niloufar Fransson, Susanne Djos, Anna Umapathy, Ganesh Östensson, Malin Milosevic, Jelena Borenäs, Marcus Hallberg, Bengt Kogner, Per Martinsson, Tommy Palmer, Ruth H. |
| spellingShingle |
Javanmardi, Niloufar Fransson, Susanne Djos, Anna Umapathy, Ganesh Östensson, Malin Milosevic, Jelena Borenäs, Marcus Hallberg, Bengt Kogner, Per Martinsson, Tommy Palmer, Ruth H. Genes, Chromosomes and Cancer Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements Cancer Research Genetics |
| author_sort |
javanmardi, niloufar |
| spelling |
Javanmardi, Niloufar Fransson, Susanne Djos, Anna Umapathy, Ganesh Östensson, Malin Milosevic, Jelena Borenäs, Marcus Hallberg, Bengt Kogner, Per Martinsson, Tommy Palmer, Ruth H. 1045-2257 1098-2264 Wiley Cancer Research Genetics http://dx.doi.org/10.1002/gcc.22790 <jats:title>Abstract</jats:title><jats:p>Gain of chromosome arm 2p is a previously described entity in neuroblastoma (NB). This genomic address is home to two important oncogenes in NB—<jats:italic>MYCN</jats:italic> and anaplastic lymphoma kinase (<jats:italic>ALK</jats:italic>). <jats:italic>MYCN</jats:italic> amplification is a critical prognostic factor coupled with poor prognosis in NB. Mutation of the ALK receptor tyrosine kinase has been described in both somatic and familial NB. Here, ALK activation occurs in the context of the full‐length receptor, exemplified by activating point mutations in NB. ALK overexpression and activation, in the absence of genetic mutation has also been described in NB. In addition, the recently identified ALK ligand ALKAL2 (previously described as FAM150B and AUGα) is also found on the distal portion of 2p, at 2p25. Here we analyze 356 NB tumor samples and discuss observations indicating that gain of 2p has implications for the development of NB. Finally, we put forward the hypothesis that the effect of 2p gain may result from a combination of <jats:italic>MYCN</jats:italic>, <jats:italic>ALK</jats:italic>, and the ALK ligand <jats:italic>ALKAL2</jats:italic>.</jats:p> Analysis of <i>ALK</i>, <i>MYCN</i>, and the ALK ligand <i>ALKAL2</i> (<i>FAM150B/AUGα</i>) in neuroblastoma patient samples with chromosome arm 2p rearrangements Genes, Chromosomes and Cancer |
| doi_str_mv |
10.1002/gcc.22790 |
| facet_avail |
Online |
| finc_class_facet |
Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9nY2MuMjI3OTA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9nY2MuMjI3OTA |
| institution |
DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
| imprint |
Wiley, 2020 |
| imprint_str_mv |
Wiley, 2020 |
| issn |
1045-2257 1098-2264 |
| issn_str_mv |
1045-2257 1098-2264 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
javanmardi2020analysisofalkmycnandthealkligandalkal2fam150baugainneuroblastomapatientsampleswithchromosomearm2prearrangements |
| publishDateSort |
2020 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Genes, Chromosomes and Cancer |
| source_id |
49 |
| title |
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_unstemmed |
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_full |
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_fullStr |
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_full_unstemmed |
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_short |
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_sort |
analysis of <i>alk</i>, <i>mycn</i>, and the alk ligand <i>alkal2</i> (<i>fam150b/augα</i>) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| topic |
Cancer Research Genetics |
| url |
http://dx.doi.org/10.1002/gcc.22790 |
| publishDate |
2020 |
| physical |
50-57 |
| description |
<jats:title>Abstract</jats:title><jats:p>Gain of chromosome arm 2p is a previously described entity in neuroblastoma (NB). This genomic address is home to two important oncogenes in NB—<jats:italic>MYCN</jats:italic> and anaplastic lymphoma kinase (<jats:italic>ALK</jats:italic>). <jats:italic>MYCN</jats:italic> amplification is a critical prognostic factor coupled with poor prognosis in NB. Mutation of the ALK receptor tyrosine kinase has been described in both somatic and familial NB. Here, ALK activation occurs in the context of the full‐length receptor, exemplified by activating point mutations in NB. ALK overexpression and activation, in the absence of genetic mutation has also been described in NB. In addition, the recently identified ALK ligand ALKAL2 (previously described as FAM150B and AUGα) is also found on the distal portion of 2p, at 2p25. Here we analyze 356 NB tumor samples and discuss observations indicating that gain of 2p has implications for the development of NB. Finally, we put forward the hypothesis that the effect of 2p gain may result from a combination of <jats:italic>MYCN</jats:italic>, <jats:italic>ALK</jats:italic>, and the ALK ligand <jats:italic>ALKAL2</jats:italic>.</jats:p> |
| container_issue |
1 |
| container_start_page |
50 |
| container_title |
Genes, Chromosomes and Cancer |
| container_volume |
59 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792342481115807745 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:36:30.074Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Analysis+of+ALK%2C+MYCN%2C+and+the+ALK+ligand+ALKAL2+%28FAM150B%2FAUG%CE%B1%29+in+neuroblastoma+patient+samples+with+chromosome+arm+2p+rearrangements&rft.date=2020-01-01&genre=article&issn=1098-2264&volume=59&issue=1&spage=50&epage=57&pages=50-57&jtitle=Genes%2C+Chromosomes+and+Cancer&atitle=Analysis+of+%3Ci%3EALK%3C%2Fi%3E%2C+%3Ci%3EMYCN%3C%2Fi%3E%2C+and+the+ALK+ligand+%3Ci%3EALKAL2%3C%2Fi%3E+%28%3Ci%3EFAM150B%2FAUG%CE%B1%3C%2Fi%3E%29+in+neuroblastoma+patient+samples+with+chromosome+arm+2p+rearrangements&aulast=Palmer&aufirst=Ruth+H.&rft_id=info%3Adoi%2F10.1002%2Fgcc.22790&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792342481115807745 |
| author | Javanmardi, Niloufar, Fransson, Susanne, Djos, Anna, Umapathy, Ganesh, Östensson, Malin, Milosevic, Jelena, Borenäs, Marcus, Hallberg, Bengt, Kogner, Per, Martinsson, Tommy, Palmer, Ruth H. |
| author_facet | Javanmardi, Niloufar, Fransson, Susanne, Djos, Anna, Umapathy, Ganesh, Östensson, Malin, Milosevic, Jelena, Borenäs, Marcus, Hallberg, Bengt, Kogner, Per, Martinsson, Tommy, Palmer, Ruth H., Javanmardi, Niloufar, Fransson, Susanne, Djos, Anna, Umapathy, Ganesh, Östensson, Malin, Milosevic, Jelena, Borenäs, Marcus, Hallberg, Bengt, Kogner, Per, Martinsson, Tommy, Palmer, Ruth H. |
| author_sort | javanmardi, niloufar |
| container_issue | 1 |
| container_start_page | 50 |
| container_title | Genes, Chromosomes and Cancer |
| container_volume | 59 |
| description | <jats:title>Abstract</jats:title><jats:p>Gain of chromosome arm 2p is a previously described entity in neuroblastoma (NB). This genomic address is home to two important oncogenes in NB—<jats:italic>MYCN</jats:italic> and anaplastic lymphoma kinase (<jats:italic>ALK</jats:italic>). <jats:italic>MYCN</jats:italic> amplification is a critical prognostic factor coupled with poor prognosis in NB. Mutation of the ALK receptor tyrosine kinase has been described in both somatic and familial NB. Here, ALK activation occurs in the context of the full‐length receptor, exemplified by activating point mutations in NB. ALK overexpression and activation, in the absence of genetic mutation has also been described in NB. In addition, the recently identified ALK ligand ALKAL2 (previously described as FAM150B and AUGα) is also found on the distal portion of 2p, at 2p25. Here we analyze 356 NB tumor samples and discuss observations indicating that gain of 2p has implications for the development of NB. Finally, we put forward the hypothesis that the effect of 2p gain may result from a combination of <jats:italic>MYCN</jats:italic>, <jats:italic>ALK</jats:italic>, and the ALK ligand <jats:italic>ALKAL2</jats:italic>.</jats:p> |
| doi_str_mv | 10.1002/gcc.22790 |
| facet_avail | Online |
| finc_class_facet | Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9nY2MuMjI3OTA |
| imprint | Wiley, 2020 |
| imprint_str_mv | Wiley, 2020 |
| institution | DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
| issn | 1045-2257, 1098-2264 |
| issn_str_mv | 1045-2257, 1098-2264 |
| language | English |
| last_indexed | 2024-03-01T16:36:30.074Z |
| match_str | javanmardi2020analysisofalkmycnandthealkligandalkal2fam150baugainneuroblastomapatientsampleswithchromosomearm2prearrangements |
| mega_collection | Wiley (CrossRef) |
| physical | 50-57 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Genes, Chromosomes and Cancer |
| source_id | 49 |
| spelling | Javanmardi, Niloufar Fransson, Susanne Djos, Anna Umapathy, Ganesh Östensson, Malin Milosevic, Jelena Borenäs, Marcus Hallberg, Bengt Kogner, Per Martinsson, Tommy Palmer, Ruth H. 1045-2257 1098-2264 Wiley Cancer Research Genetics http://dx.doi.org/10.1002/gcc.22790 <jats:title>Abstract</jats:title><jats:p>Gain of chromosome arm 2p is a previously described entity in neuroblastoma (NB). This genomic address is home to two important oncogenes in NB—<jats:italic>MYCN</jats:italic> and anaplastic lymphoma kinase (<jats:italic>ALK</jats:italic>). <jats:italic>MYCN</jats:italic> amplification is a critical prognostic factor coupled with poor prognosis in NB. Mutation of the ALK receptor tyrosine kinase has been described in both somatic and familial NB. Here, ALK activation occurs in the context of the full‐length receptor, exemplified by activating point mutations in NB. ALK overexpression and activation, in the absence of genetic mutation has also been described in NB. In addition, the recently identified ALK ligand ALKAL2 (previously described as FAM150B and AUGα) is also found on the distal portion of 2p, at 2p25. Here we analyze 356 NB tumor samples and discuss observations indicating that gain of 2p has implications for the development of NB. Finally, we put forward the hypothesis that the effect of 2p gain may result from a combination of <jats:italic>MYCN</jats:italic>, <jats:italic>ALK</jats:italic>, and the ALK ligand <jats:italic>ALKAL2</jats:italic>.</jats:p> Analysis of <i>ALK</i>, <i>MYCN</i>, and the ALK ligand <i>ALKAL2</i> (<i>FAM150B/AUGα</i>) in neuroblastoma patient samples with chromosome arm 2p rearrangements Genes, Chromosomes and Cancer |
| spellingShingle | Javanmardi, Niloufar, Fransson, Susanne, Djos, Anna, Umapathy, Ganesh, Östensson, Malin, Milosevic, Jelena, Borenäs, Marcus, Hallberg, Bengt, Kogner, Per, Martinsson, Tommy, Palmer, Ruth H., Genes, Chromosomes and Cancer, Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements, Cancer Research, Genetics |
| title | Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_full | Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_fullStr | Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_full_unstemmed | Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_short | Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_sort | analysis of <i>alk</i>, <i>mycn</i>, and the alk ligand <i>alkal2</i> (<i>fam150b/augα</i>) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| title_unstemmed | Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements |
| topic | Cancer Research, Genetics |
| url | http://dx.doi.org/10.1002/gcc.22790 |